Heather Mason-Suares

Dr. Heather Mason-Suares

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Current Opinion in Genetics & Development
Verified
Journal Article
Closed access
DHDerick C Hoskinson
Derick C Hoskinson
ADAdrian M Dubuc
Adrian M Dubuc
HMHeather Mason-Suares
Heather Mason-Suares

9 March 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
EHErin M. Higgins
Erin M. Higgins
JBJ. Martijn Bos
J. Martijn Bos
HMHeather Mason-Suares
Heather Mason-Suares
DTDavid J. Tester
David J. Tester
JAJaeger P. Ackerman
Jaeger P. Ackerman
MAMichael J. Ackerman
Michael J. Ackerman
Noonan syndrome (NS; MIM 163950) is an autosomal dominant disorder and a member of a family of developmental disorders termed “RASopathies,” which are caused mainly by gain-of-function mutations in genes encoding RAS/MAPK signaling pathway proteins. Whole exome sequencing (WES) and trio-based genomic triangulation of a 15-year-old female with a clinical diagnosis of NS and concomitant cardiac hypertrophy and her unaffected parents identified a de novo variant in MRAS -encoded RAS-related protein 3 as the cause of her disease. Mutation analysis using in silico mutation prediction tools and molecular dynamics simulations predicted the identified variant, p.Gly23Val-MRAS, to be damaging to normal protein function and adversely affect effector interaction regions and the GTP-binding site. Subsequent ectopic expression experiments revealed a 40-fold increase in MRAS activation for p.Gly23Val-MRAS compared with WT-MRAS. Additional biochemical assays demonstrated enhanced activation of both RAS/MAPK pathway signaling and downstream gene expression in cells expressing p.Gly23Val-MRAS. Mutational analysis of MRAS in a cohort of 109 unrelated patients with phenotype-positive/genotype-negative NS and cardiac hypertrophy yielded another patient with a sporadic de novo MRAS variant (p.Thr68Ile, c.203C>T). Herein, we describe the discovery of mutations in MRAS in patients with NS and cardiac hypertrophy, establishing MRAS as the newest NS with cardiac hypertrophy-susceptibility gene.

26 February 2016 in Prenatal Diagnosis
Verified
Journal Article
Open access
PDF file
FHFahad Hakami
Fahad Hakami
MDMitchell W. Dillon
Mitchell W. Dillon
MLMatthew Lebo
Matthew Lebo
HMHeather Mason-Suares
Heather Mason-Suares
Objectives Noonan spectrum disorders (NSDs) occur in 1:1000–2500 live births. Currently, there are no guidelines for prenatal molecular genetic testing for NSDs. Recent studies recommend prenatal testing for NSDs when ultrasonography detects two or more associated abnormalities. A stronger association between ultrasound findings and NSDs would enable more informed prenatal genetic testing. Methods A total of 212 newborns (0–12 weeks) with prenatal ultrasound findings and a clinical suspicion of a NSD were referred for molecular genetic testing. Of these, 159/212 newborns tested had a single ultrasound abnormality and 53/212 newborns had two or more. Testing was performed by either a microarray-based resequencing assay or next generation sequencing of RAS/MAPK pathway genes associated with NSDs. Prenatal ultrasound findings in positive and negative cases were compared. Results A disease-causing variant was identified in 21.7% (46/212) of newborns tested. Of these positive cases, 67.4% (31/46) had only one ultrasound abnormality reported. The rate of detecting a disease-causing variant in cases with one ultrasound finding was 19.5% (31/159), which was not significantly different (p-value = 0.36) than that in cases with two or more ultrasound findings (28.3%; 15/53). Conclusions Prenatal molecular testing for NSDs should be considered even in the presence of a single associated abnormal ultrasound finding. © 2016 John Wiley & Sons, Ltd.

8 June 2016 in Current Genetic Medicine Reports
Verified
Journal Article
Closed access
PDF file
HMHeather Mason-Suares
Heather Mason-Suares
LLLatrice Landry
Latrice Landry
MLMatthew Lebo
Matthew Lebo

Verified
Journal Article
Open access
PDF file
HMHeather Mason-Suares
Heather Mason-Suares
DSDavid A. Sweetser
David A. Sweetser
NLNeal I. Lindeman
Neal I. Lindeman
CMCynthia C. Morton
Cynthia C. Morton
The era of personalized medicine has arrived, and with it a need for leaders in this discipline. This generation of trainees requires a cadre of new skill sets to lead the implementation of personalized medicine into mainstream healthcare. Traditional training programs no longer provide trainees with all the skills they will need to optimize implementation of this revolution now underway in medicine. Today’s trainees must manage clinical teams, act as clinical and molecular diagnostic consultants, train other healthcare professionals, teach future generations, and be knowledgeable about clinical trials to facilitate genomic-based therapies. To prepare trainees for the transition to junior faculty positions, contemporary genomic training programs must emphasize the development of these management, teaching, and clinical skills.

17 April 2025 in Genetics in Medicine Open
Verified
Journal Article
Open access
EWEmma H. Wilcox
Emma H. Wilcox
RWRyan F. Webb
Ryan F. Webb
KTKezang C. Tshering
Kezang C. Tshering
MHMadeline Y. Hughes
Madeline Y. Hughes
HCHélène Cavé
Hélène Cavé
RWRyan Webb
Ryan Webb
The ClinGen RASopathy (RAS) Variant Curation Expert Panel (VCEP) previously established RASopathy specifications to the American College of Medical Genetics and Genomics (ACMG) and Association of Molecular Pathology (AMP) variant classification framework for more consistent and accurate variant classification. Advances in the understanding of RASopathies and new clinical genetic testing algorithms required updated specifications. The RAS Gene Curation Expert Panel recurated 6 gene-disease relationships, and the RAS VCEP evaluated the previous specifications to develop updated RASopathy specifications for the ACMG/AMP framework. The performance of these updated specifications was tested by reassessing 59 previously classified variants and 88 new pilot variants. Five gene-disease relationships were upgraded to Definitive, whereas 1 was upgraded to Moderate. Updated specifications were applied to 11 ACMG/AMP criteria for disorders with a dominant inheritance, 3 criteria for recessive inheritance, and 4 criteria to align with recommendations from the ClinGen Sequence Variant Interpretation Working Group. Assessment of variants demonstrated no major shifts in classifications compared with previous RAS VCEP or ClinVar classifications. Updated RASopathy specifications improve the classification of variants associated with recessive disease and observed in exome/genome cases. Most of these specifications may also be used as a baseline for other rare Mendelian disorders.